Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2011-10-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Jianpi Qushi Huatan Decoction in the Treatment of Polycystic Ovary Syndrome
NCT05976295
Efficacy of Bushen Huatan Decoction in the Treatment of Polycystic Ovary Syndrome
NCT05976308
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS
NCT03264638
Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome
NCT04120597
Serum Metabolomics Study of Traditional Chinese Medicine Formula （Shen Qi Tiao Ti Formula） Intervention to Polycystic Ovary Syndrome
NCT03623451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tanshinone
tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
tanshinone
tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
tanshinone placebo
placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
tanshinone placebo
placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tanshinone
tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
tanshinone placebo
placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of women from 18 to 35 years；
* No desire of children within 6 month and use condoms for contraception.
Exclusion Criteria
* Patients with other androgen excess endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, Cushing syndrome, severe insulin resistance, thyroid dysfunction；
* Patients with history of sever cardiac , pulmonary, hepatic, renal, neurologic disease or mental illness；
* Pregnancy or lactation.
18 Years
36 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heilongjiang University of Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoke Wu
Professor and Chairman Dept Obs & Gyn, First Affiliated Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoke Wu, docotor
Role: STUDY_CHAIR
The First Affliated Hospital,Heilongjiang University of Chinese Medicine .
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heilongjiang University of Chinese Medicine
Harbin, Heilongjiang, China
Huaian Maternal and Child Health Hospital
Huaian, Jiangsu, China
Lianyungang Maternal and Child Health Hospital
Lianyungang, Jiangsu, China
JiangXi University of Traditional Chinese Medicine
Nanchang, Jiangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Tanshinone-HLJUCM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.